Biodiversity 2 Drugs

What exactly does Biodiversity2Drugs aim to do?
Biodiversity2Drugs, led by the Institute of Pharmacology at the Medical University of Vienna, is a global collaboration dedicated to identifying bioactive peptides from a range of natural sources — e.g. plants, insects, spiders and marine organisms — for biochemical studies and therapeutic development. Through evolution-driven sampling, advanced bioinformatics including artificial intelligence, sustainable chemistry, and high-throughput screening, the project seeks to create effective, sustainable drugs for treating chronic pain, autoimmune diseases, and other major health issues, and understand their mechanism-of-action.

What (social) impact are we trying to achieve?
The project promotes sustainable, biodiversity-based drug discovery, emphasizing the pharmacological potential of natural peptides. By raising awareness about biodiversity's role in health, it aims to inspire conservation efforts and engage the public, policymakers, and industry in supporting the protection of natural resources.

Why is collaboration with foreign partners so important?
Working with 25 partners across 18 countries combines expertise in ecology, bioinformatics, structural biology, chemistry and pharmacology, fostering resource efficiency and innovation. This international approach supports ethical & sustainable sampling and ensures global knowledge-sharing, helping to address biodiversity loss and health challenges more effectively.